TEL AVIV, Israel – May 24, 2023 – Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board. Pharmaceutical industry veteran Oscar Puig, Ph.D. has been named the VP of Transitional Medicine & Diagnostics at Nucleai, while Suzana Couto, the Head of Pathology at Neomorph Inc, has been appointed as a scientific advisor for the company.
“I’m very pleased to welcome Dr. Puig and Dr. Couto to be part of Nucleai’s efforts on the forefront of spatial biology,” said Avi Veidman, Chief Executive Officer of Nucleai. “Their expertise and experience in top pharmaceutical companies perfectly complement Nucleai’s focus on serving the pharmaceutical industry. Dr. Puig and Dr. Couto are extraordinarily well respected and will surely help us increase our traction to drive Nucleai’s technology deeper into pharma and biopharma processes, workflows and clinical trials.”